Sign inJoin waitlistJoin the waitlist

AC

Aine Clements

Physician · Ohiohealth

Credentials: · · · · ·

History

Ohiohealth
Present

Gynecologic Oncology
Ohio State University Hospital
2011–2014
Obstetrics and Gynecology
Women and Infants Hospital of Rhode Island
2006–2010
Internal Medicine
Boston University Medical Center
2005–2006
Alpert Medical School
2001–2005

Research

OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab
Gynecologic Oncology · 2022 · 66 citations
Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study
JCO Precision Oncology · 2021 · 26 citations
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258
Gynecologic Oncology · 2025 · First of 23 authors · Corresponding · 23 citations

KR
Kellie Rath
8 papers · 1 as a fellow
David Cohn
7 papers
Ann Klopp
4 papers · 1 as a fellow
Angeles Secord
3 papers
Casey Cosgrove
3 papers · 1 as a fellow
CC
Corinne Calo
3 papers · 2 as a resident
David O'Malley
3 papers
Floor Backes
3 papers · 3 as a fellow
Gottfried Konecny
3 papers
Jeffrey Fowler
3 papers
MR
Maggie Rosen
3 papers · 3 as a resident
ML
Margaret Liang
3 papers · 3 as a resident

Clinical trials

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034
Letrozole in Uterine Leiomyosarcoma
Site PI · Recruiting · Phase 2
GOG Foundation
2024–2029
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027